Unique Treatment Options
The Lankenau Institute for Medical Research (LIMR) is leading new ways to prognose and treat human disease through a unique research model that combines non-profit laboratory research, small company start-ups that help translate laboratory discoveries to the clinic, and clinical research that can directly impact patient care. Located on the campus of Lankenau Medical Center, LIMR is one of only a few independent, academically-oriented hospital-associated research institutes in the United States.
LIMR researchers move their discoveries from lab bench to bedside through the creation of a unique environment where so-called 'translational research' that moves between the laboratory and clinic can create greater impact in the commercial as well as the clinical setting.
LIMR scientists focus their research on cancer, cardiovascular disease and diabetes. In cancer, their exciting work is expanding studies of disease modifier genes, pioneering nanotechnology-based gene therapies and new pharmacological agents to treat cancer, including by restoring immune defenses that can attack tumors in new ways. In cardiovascular disease, our researchers focus on cardiac arrhythmias, hypertension and atherosclerosis, using basic and preclinical findings to create new prognostic and therapeutic tools for clinical use.
The LIMR faculty hold academic appointments at the Jefferson Medical School at Thomas Jefferson University, where they collaborate with scientists and clinical researchers, as well as the doctors of Lankenau Medical Center and other Main Line Health hospitals. These close relationships foster many new, innovative ideas that are tested in our laboratories, commercialized by our business development unit, LDI, and eventually brought to patients through our clinical trials. LIMR is at the forefront of translational research to develop diagnostic, prognostic and therapeutic tools for a healthier population. For more information, please visit us at www.limr.org.
Academic and Clinical Research Support
The LIMR Chemical Genomics Center (LCGC) is a new entity created to bridge a major gap in the development and commercialization of biomedical technology discovered in universities by providing scientists access to unique collections of diverse drug-like compounds heretofore available only to major pharmaceutical companies. This wholly-owned subsidiary of LIMR stores and arrays up to ten million compounds for high throughput screening to discover new drug leads on novel cell signaling targets with 500% improved efficiency compared with prevailing protocols.
The Center for Human Antibody Technology (CHAT) is a LIMR core facility that uses a new and powerful human antibody cloning platform technology. This regional resource is a state-of-the-art, high throughput antibody production and screening facility that produces human antibodies for academic use as well as the treatment of infectious disease, cancer, and neurological illnesses.
The LIMR Cardiovascular Research Group (CRG) provides pharmaceutical companies worldwide with a complete range of cardiac safety assessment services designed to accelerate the drug-development process. The CRG offers an integrated portfolio of cardiac safety assays from cell to organ levels, which include the wedge preparation assay, a hERG potassium current analysis, INa and ICa screening, a human cardiomyocyte ion channel assay, and an action potential assay.
Lankenau Medical Center
for Medical Research (LIMR)
LIMR Development, Inc. (LDI)
Genomics Center, Inc.
LIMR Biotech Incubator
Research Group -
Assessment Services Support Lankenau
LDI Research Products